AtriCure (ATRC) Q2 2023: Encompass Clamp Penetration Tops 30%, Driving 23% Open Ablation Growth
Encompass Clamp adoption crossed a critical penetration threshold, fueling broad-based growth and operational leverage for AtriCure. The company’s diversified franchises delivered strong results, with open ablation, appendage management, and pain management all outpacing expectations. Management’s focus on durable market expansion, pipeline investment, and clinical trial acceleration sets up a multi-year growth trajectory, though near-term guidance remains conservative amid capacity and R&D spend ramp.
Summary
- Open Ablation Inflection: Encompass Clamp adoption surpassed 30% penetration, unlocking higher procedure volumes.
- Pipeline and Clinical Expansion: Accelerated LEAPS trial enrollment and next-gen product development signal long-term growth bets.
- Margin and Investment Balance: Near-term margin guidance remains cautious as R&D and capacity projects scale in H2.
Business Overview
AtriCure is a medical device company specializing in cardiac surgical and pain management solutions. Its core franchises include open ablation (devices for treating atrial fibrillation, or AFib), appendage management (Atriclip line for stroke prevention), pain management (Cryosphere nerve block), and minimally invasive ablation (EpiSense system for hybrid therapy). Revenue is diversified across these platforms, with appendage management representing about 40% of total sales. The company generates revenue from device sales to hospitals and surgical centers, with a growing international footprint.
Performance Analysis
AtriCure delivered broad-based revenue growth across all major franchises and geographies in Q2. Open ablation, led by the Encompass Clamp, achieved 23% worldwide growth, reflecting rapid adoption and increased penetration in cardiac surgery markets. Appendage management, anchored by the Atriclip product line, grew 17% year-over-year and accounted for roughly 40% of total revenue, buoyed by strong U.S. and international demand. Pain management posted 26% growth, with Cryosphere Probe sales surpassing $100 million life-to-date, though market penetration remains low, signaling further upside.
International markets also delivered robust results, with Europe and Asia Pacific posting over 19% growth. Gross margin improved 130 basis points year-over-year to 76.4%, driven by manufacturing efficiencies, though management flagged coming headwinds from product mix and one-time capacity investments in the second half. Adjusted EBITDA turned positive, highlighting operational leverage, while operating expenses increased modestly as the company ramped R&D and clinical trial activity, particularly for the LEAPS stroke prevention trial.
- Encompass Clamp Drives Volume: Penetration exceeded 30% of procedures, expanding both site count and within-site utilization.
- LEAPS Trial Momentum: Nearly 500 patients enrolled in six months, with site expansion accelerating in North America and Europe.
- Balanced Cost Discipline: SG&A leverage and targeted R&D spend supported profitability, with significant H2 investment flagged.
Overall, AtriCure’s results reflected durable demand drivers, operational discipline, and early returns on pipeline investments, while management set expectations for increased spending to support future growth.
Executive Commentary
"We are thrilled to surpass the $100 million mark this quarter and remain excited about the trajectory of our business... we achieved positive adjusted EBITDA of $8 million in the quarter, driven by our robust top-line performance and improving operating leverage throughout the entire business."
Mike Carroll, President and CEO
"Our operations team has done some really fantastic work to maintain the stability of our manufacturing... Part of that is in the coming months are expecting some pressure to gross margin from capacity improvement projects that have been planned for this year and will ultimately benefit our operations long-term."
Angie Weirich, Chief Financial Officer
Strategic Positioning
1. Encompass Clamp Penetration and Open Ablation Leadership
The Encompass Clamp, a device for simplifying and accelerating cardiac ablation, has now achieved penetration in over 30% of relevant procedures and 40% of sites, marking an inflection in adoption. This product’s ease of use and clinical results are driving increased ablation rates among surgeons who previously did not perform the procedure, supporting both volume and share gains. Management anticipates continued multi-year growth as more sites and surgeons adopt the technology.
2. Pipeline Investment and Clinical Trial Acceleration
The LEAPS trial, studying prophylactic use of Atriclip for stroke prevention, is well ahead of enrollment targets, with nearly 500 patients enrolled and a significant ramp in trial sites planned. This trial has the potential to expand the addressable market materially by targeting patients without preoperative AFib. Additionally, next-generation product development in both cryoablation and appendage management is underway, with strategic R&D investments flagged for the second half.
3. International Expansion and Market Diversification
International revenue growth exceeded 19%, driven by procedure volume and new product adoption in Europe and Asia Pacific. While pain management penetration remains nascent outside the U.S., early feedback is positive and the company is building out dedicated teams to support expansion. Regulatory approvals for Encompass Clamp in Europe and Australia are in process, representing further upside.
4. Margin Leverage and Capital Allocation Discipline
Gross margin improvement reflected operational efficiencies, but management is proactively investing in capacity and R&D, tempering near-term margin expansion. The acquisition of foundational Atriclip patents eliminated future royalty obligations and provides long-term control over a key IP portfolio, supporting both profitability and innovation flexibility.
Key Considerations
This quarter’s results highlight AtriCure’s ability to drive growth across multiple platforms while balancing investment and profitability. Management’s approach is measured, emphasizing sustainable adoption, clinical evidence generation, and operational discipline.
Key Considerations:
- Open Ablation Penetration Unlocks Multi-Year Growth: Encompass Clamp is driving both new site adoption and deeper utilization within existing accounts, with runway to 100% penetration.
- Clinical Evidence as a Strategic Moat: The LEAPS trial and other studies are building a foundation for future market expansion and reimbursement support.
- Margin Management Amid Growth Investments: Management is signaling short-term gross margin headwinds due to capacity projects and product mix, offset by long-term leverage potential.
- Global Expansion Still Early: International pain management and Encompass Clamp launches are in the early innings, with regulatory, reimbursement, and operational hurdles to clear.
Risks
Key risks include execution on global product rollouts, regulatory timelines for new approvals, and the potential for clinical trial delays or adverse outcomes. Margin compression from product and geographic mix, as well as escalating R&D spend, could pressure near-term profitability. The company’s guidance remains conservative, reflecting seasonality and the need for sustained operational discipline amid rapid expansion.
Forward Outlook
For Q3 2023, AtriCure guided to:
- Slight sequential revenue decline due to normal summer seasonality
- Gross margin comparable to full-year 2022, with capacity investments and product mix as headwinds
For full-year 2023, management raised guidance:
- Revenue of $392 million to $395 million, reflecting 19% to 20% growth
- Positive adjusted EBITDA of approximately $12 million
- Adjusted loss per share of $0.92 to $0.94
Management highlighted several factors that will shape the back half:
- Increased R&D spend, especially for LEAPS trial site expansion and next-gen product development
- Continued momentum in open ablation and appendage management, with cautious outlook for hybrid therapy ramp
Takeaways
AtriCure’s Q2 results underscore the power of diversified growth drivers and operational leverage, with open ablation and appendage management leading the charge.
- Open Franchise Inflection: Encompass Clamp adoption is unlocking higher procedure volumes and deeper site utilization, with significant penetration runway.
- Pipeline and Evidence Build: Accelerated LEAPS trial enrollment and ongoing R&D investment signal a multi-year growth opportunity and reinforce the clinical moat.
- Watch for Margin and Spend Dynamics: Investors should monitor the balance between near-term margin pressure and the long-term payoff from pipeline and capacity investments.
Conclusion
AtriCure is executing on a strategy of broad-based growth, clinical leadership, and operational discipline, positioning the company for durable expansion. While near-term margin guidance is cautious due to investment ramp, the company’s diversified franchises and accelerating clinical pipeline underpin a compelling long-term outlook.
Industry Read-Through
AtriCure’s results reinforce the importance of procedural innovation and clinical data in driving adoption within cardiac surgery and pain management markets. The rapid penetration of the Encompass Clamp highlights the value of user-friendly, workflow-enhancing devices in accelerating standard-of-care shifts. Clinical trial acceleration, especially in stroke prevention, signals that companies investing in large-scale, evidence-generating studies are best positioned for future reimbursement and market expansion. The balance of operational leverage and disciplined investment is a key theme for medtech peers navigating growth and profitability trade-offs in a post-pandemic environment.